Verastem says RAMP 205 trial shows 52% response rate for avutometinib-defactinib combo in first-line metastatic pancreatic cancer

Verastem, Inc.

Verastem, Inc.

VSTM

0.00
  • Verastem reported positive updated interim results from RAMP 205 testing avutometinib with defactinib alongside standard chemotherapy in first-line metastatic pancreatic cancer.
  • Results have not been presented at a medical meeting; the company flagged plans to share the data in the future.
  • The regimen showed encouraging early survival and response signals, with broad evidence of tumor reduction and no new safety concerns.
  • Management tied next steps to final survival readouts, while also weighing future development options or potential strategic collaborations in the indication.
  • PanCAN backing included a USD 3.8 million Therapeutic Accelerator Award to support the front-line metastatic pancreatic cancer program.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Verastem Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260617680929) on June 17, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.